GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Casp9 | increases activity | ISO | CASP9 (Homo sapiens) | 6480464 | CTD | sorafenib results in increased activity of CASP9 protein | PMID:21293487 PMID:25416439 | Casp9 | increases cleavage | ISO | CASP9 (Homo sapiens) | 6480464 | CTD | sorafenib results in increased cleavage of CASP9 protein | PMID:18200035 PMID:20054642 PMID:20071162 | Casp9 | multiple interactions | ISO | CASP9 (Homo sapiens) | 6480464 | CTD | [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP9 protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP9 protein | PMID:16109713 PMID:16985072 PMID:17909059 PMID:20071162 PMID:20117835 PMID:25416439 | |
Go Back to source page | Continue to Ontology report |